Restoring Balance.

Aldeyra is at the forefront of drug research, developing medicines to treat ocular and systemic conditions that are not adequately addressed by current treatments. emagine partnered with Aldeyra to refresh their brand and present their mission on the web in a user-friendly and dynamic way.

View the website here: https://www.aldeyra.com/

Handcrafted Design

emagine created a hand-drawn logo at the start of the web project with Aldeyra, to embody the themes of restoring balance and capture a look that was instantaneously recognizable as Aldeyra. From concept to implementation, the animated version of the Aldeyra logo created by emagine was eventually featured by Nasdaq on Aldeyra’s 5th anniversary.

logo concepts on sketch pad

aldeyra banner

Site Expansion

Aldeyra’s project with emagine took an existing website with little content and expanded the site into a more complete web presence. The homepage features their pipelines and latest news at a glance, leading into more detail for all users of the site. Our consulting on site architecture led into a comprehensive content workshop and additionally assisted in copywriting services to better tell the story of the important work happening at Aldeyra.

Doctor and patient in ophthalmology clinic

emagine’s team recreated the Aldeyra brand essence with a hand-drawn logo for their new web identity. At the end of the project, we partnered with Aldeyra again to animate their logo for the Nasdaq billboard in New York

Studio shot of a man opening his eyes against a dark background

Besides a more user-friendly site architecture and aesthetically pleasing site, the new website for Aldeyra introduced WordPress as their new CMS. emagine designed a much easier to use CMS for the team at Aldeyra to add news and updates instantly, without requiring heavy technical knowledge.

Science background with molecules and atoms

Aldeyra’s research and phases of clinical trials are now available in a dynamic and easy to understand format for all visitors, including patients of these conditions and other drug developers.

Watch the emagineHealth Reel